Economic Impact of Clostridium difficile Infection in a Multihospital Cohort of Academic Health Centers

Pharmacotherapy

Volumn 31, Issue 6, 2011, Pages 546-551

  Pakyz, Amy ^a   Carroll, Norman V ^a   Harpe, Spencer E ^a   Oinonen, Michael ^b   Polk, Ronald E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b University HealthSystem Consortium ^*  (United States)

Author keywords

CDI; Clostridium difficile infection; Economic evaluation; Health care associated infection; Nosocomial infection

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSIS RELATED GROUP; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CENTER; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; CROSS INFECTION; FEMALE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; LINEAR MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 79957623658     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.6.546     Document Type: Article

References (21)

1. Ricciardi R, Rotherberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007;142:624-31.
2. Voelker R. Increased Clostridium difficile virulence demands new treatment approach. JAMA 2010;303:2017-19.
3. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-41.
4. Centers for Medicare and Medicaid Services. HHS, Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2008 rates. Fed Regist 2007;72:47129-8175.
5. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53. (Pubitemid 34062235)
6. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable cost of Clostridium difficile-associated disease in nonsurgical patients. Clin Infect Dis 2008;46:497-504.
7. Song X, Bartlett JG, Speck K, Naegeli A, Carroll K, Perl TM. Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008;29:823-8.
8. Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. Costs of nosocomial Clostridium difficile-associated diarrhoea. J Hosp Infect 2008;70:15-20.
9. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-27.
10. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of C. difficile infection. Infect Control Hosp Epidemiol 2009;30:57-66.
11. Pakyz AL, MacDougall C, Oinonen M, Polk RE. Trends in antibacterial use in U.S. academic health centers. Arch Intern Med 2008;168:2254-60.
12. Schmiedeskamp M, Harpe SE, Polk RE, Oinonen M, Pakyz AL. Using ICD-9-CM codes and drug utilization data to identify nosocomial Clostridium difficile infection. Infect Control Hosp Epidemiol 2009;30:1070-6.
13. 3M Health Information Systems. All patient refined diagnosis related groups (APR-DRG), version 24.0, methodology overview. Wallingford, CT: 3M Health Information Systems, 2006.
14. Schwartz M, Young DW, Siegrist R. The ratio of costs to charges: how good a basis for estimating costs? Inquiry 1995-1996;32:476-81.
15. Afifi AA, Kotlerman JB, Ettner SL, Cowan M. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007;28:95-111. (Pubitemid 46833335)
16. Duan N. Smearing estimate: a non-parametric retransformation method. J Am Stat Assoc 1983;78:605-10.
17. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
18. Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010;74:309-18.
19. Spangler CA, Risi GF Jr. The cost of hospital acquired Clostridium difficile-associated diarrhea [poster 171]. Poster presentation at the 17th annual meeting of the Society for Healthcare Epidemiology of America, Baltimore, MD, April 14-17, 2007.
20. Reed JF, Edris BA, Eid S. Clostridium difficile: the new epidemic [poster 816]. Poster presentation at the 45th annual meeting of the Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.
21. Perencevich EN, Thom KA. Preventing Clostridium difficile-associated disease: is it time to pay the piper? Infect Control Hosp Epidemiol 2008;29:29-31.